RLYB Fundamental Analysis - RALLYBIO CORP

Fundamental Rating

RLYB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RLYB as it has an excellent financial health rating, but there are worries on the profitability. RLYB is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year RLYB has reported negative net income.

In the past year RLYB has reported a negative cash flow from operations.

In the past 5 years RLYB always reported negative net income.

RLYB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of RLYB (-83.10%) is worse than 71.15% of its industry peers.

RLYB has a Return On Equity (-89.11%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-83.1%
ROE	-89.11%
ROIC	N/A

ROA(3y)-62.09%

ROA(5y)-46.14%

ROE(3y)-67.77%

ROE(5y)-49.9%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RLYB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RLYB does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for RLYB has been increased compared to 1 year ago.

The number of shares outstanding for RLYB has been increased compared to 5 years ago.

There is no outstanding debt for RLYB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -6.15, we must say that RLYB is in the distress zone and has some risk of bankruptcy.

RLYB's Altman-Z score of -6.15 is on the low side compared to the rest of the industry. RLYB is outperformed by 63.98% of its industry peers.

RLYB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-6.15

ROIC/WACCN/A

WACC9.7%

2.3 Liquidity

RLYB has a Current Ratio of 14.68. This indicates that RLYB is financially healthy and has no problem in meeting its short term obligations.

RLYB has a better Current ratio (14.68) than 87.81% of its industry peers.

RLYB has a Quick Ratio of 14.68. This indicates that RLYB is financially healthy and has no problem in meeting its short term obligations.

RLYB's Quick ratio of 14.68 is amongst the best of the industry. RLYB outperforms 87.81% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	14.68
Quick Ratio	14.68

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.02% over the past year.

EPS 1Y (TTM)42.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%55.32%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RLYB will show a small growth in Earnings Per Share. The EPS will grow by 2.36% on average per year.

The Revenue is expected to grow by 256.09% on average over the next years. This is a very strong growth

EPS Next Y36.16%

EPS Next 2Y15.71%

EPS Next 3Y9.06%

EPS Next 5Y2.36%

Revenue Next Year-69.46%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y256.09%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RLYB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RLYB. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y15.71%

EPS Next 3Y9.06%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RLYB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

RALLYBIO CORP

NASDAQ:RLYB (7/18/2025, 3:16:54 PM)

0.448

-0.01 (-1.47%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-08 2025-05-08/bmo

Earnings (Next)08-06 2025-08-06/bmo

Inst Owners70.58%

Inst Owner Change0%

Ins Owners2.39%

Ins Owner Change0%

Market Cap18.64M

Analysts74.55

Price Target1.02 (127.68%)

Short Float %0.94%

Short Ratio0.1

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)17.67%

Min EPS beat(2)14.53%

Max EPS beat(2)20.81%

EPS beat(4)4

Avg EPS beat(4)16.5%

Min EPS beat(4)3.01%

Max EPS beat(4)27.67%

EPS beat(8)7

Avg EPS beat(8)9.83%

EPS beat(12)10

Avg EPS beat(12)9.48%

EPS beat(16)12

Avg EPS beat(16)10.33%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-87.88%

EPS NQ rev (1m)0%

EPS NQ rev (3m)1.01%

EPS NY rev (1m)-0.6%

EPS NY rev (3m)22.08%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)94.34%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	21.98
P/FCF	N/A
P/OCF	N/A
P/B	0.34
P/tB	0.34
EV/EBITDA	N/A

EPS(TTM)-1.09

EYN/A

EPS(NY)-0.89

Fwd EYN/A

FCF(TTM)-1.06

FCFYN/A

OCF(TTM)-1.06

OCFYN/A

SpS0.02

BVpS1.3

TBVpS1.3

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-83.1%
ROE	-89.11%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-62.09%

ROA(5y)-46.14%

ROE(3y)-67.77%

ROE(5y)-49.9%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	14.68
Quick Ratio	14.68
Altman-Z	-6.15

F-Score5

WACC9.7%

ROIC/WACCN/A

Cap/Depr(3y)12.47%

Cap/Depr(5y)114.15%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)42.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%55.32%

EPS Next Y36.16%

EPS Next 2Y15.71%

EPS Next 3Y9.06%

EPS Next 5Y2.36%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year-69.46%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y256.09%

EBIT growth 1Y37.29%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-7.15%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y29.36%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y29.35%

OCF growth 3YN/A

OCF growth 5YN/A

RALLYBIO CORP (RLYB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens